Market cap
$179m
Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
In October 2025, Apotex received Health Canada approval for LOQTORZI for the treatment of recurrent unresectable or metastatic nasopharyngeal cancer. Results of Operations Comparison of Three and Six Months Ended June 30, 2026 and 2025 Revenue The increases in LOQTORZI net revenue for the three and six months ended June 30, 2026, compared to the same periods in the prior year, were driven primarily by volume growth of LOQTORZI. We expect net revenue from continuing operations in 2026 to be higher than in 2025 because of continued growth of LOQTORZI. …Coherus Oncology, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05